Radiation Therapy Quality Assurance Phantoms Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Linear Accelerators, Cobalt-60, High-Dose Radiation, and Low-Dose Radiation), By Therapy (Photon Beam Radiation Therapy, Advanced 3-D Conformal Radiation Therapy, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, Intraoperative Radiotherapy, Neutron Beam Therapy, and Brachytherapy), By Application (Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head, And Neck Cancers, Skin Cancer, and Other), By Region and Competition, 2020-2030F

Market Overview

The Global Radiation Therapy Quality Assurance Phantoms Market was valued at USD 100.24 million in 2024 and is expected to reach USD 147.12 million by 2030 with a CAGR of 6.60% during the forecast period. The global market for Radiation Therapy Quality Assurance Phantoms is experiencing significant growth, driven by the growing demand for the treatment of chronic diseases such as different types of cancers along with growing concerns about the need for a formal radiation therapy quality assurance program that enables radiation physicians to improve patient safety and provide care. Also growing aging populations are more susceptible to different types of chronic diseases which will further boost market growth during the forecast period. 

Besides, growing awareness about new therapy related to oncology is further expected to support the Global Radiation Therapy Quality Assurance Phantoms Market during the forecast period. Furthermore, the impending patent expiry of biological products and development of new therapies, and the increasing number of new players are further expected to increase the demand for radiation therapy quality assurance phantoms, thereby supporting the market growth.

Key Market Drivers

Rising Global Cancer Incidence and Demand for Precision Radiotherapy

The increasing prevalence of cancer globally is a key driver propelling the demand for radiation therapy, and consequently, quality assurance phantoms. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The growing burden of cancer has led to widespread investments in radiotherapy infrastructure, especially in developing countries, and increased utilization of advanced modalities such as intensity-modulated radiotherapy (IMRT) and stereotactic radiosurgery (SRS). These highly targeted treatments require stringent QA protocols, where phantoms simulate human tissue to validate dose delivery, spatial accuracy, and beam alignment. National health agencies such as the U.S. National Cancer Institute (NCI) and the International Atomic Energy Agency (IAEA) have recommended standardized QA guidelines using phantoms to ensure patient safety and therapeutic success.

Moreover, the Global Cancer Observatory (GLOBOCAN) projects that the number of new cancer cases worldwide will rise to over 28 million by 2040, further amplifying the demand for precision radiotherapy systems. As healthcare systems expand radiotherapy access, especially in Asia and Africa, the demand for robust QA phantoms to verify and maintain accuracy in these technologies is expected to grow significantly.

Regulatory Pressure and Accreditation Requirements

Increasing emphasis on radiation safety and regulatory compliance is also driving the adoption of QA phantoms across hospitals and radiotherapy centers. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate strict quality checks for radiotherapy devices. Additionally, accreditation agencies such as the American College of Radiology (ACR) and the International Organization for Standardization (ISO) require periodic quality assurance validations using standardized phantoms. QA phantoms are essential to conduct acceptance testing, routine performance checks, and calibration of radiation therapy machines such as linear accelerators. They help in measuring spatial and dosimetric accuracy and ensure adherence to acceptable limits of error (often <5%). Facilities that fail to demonstrate QA protocols through phantom-based evaluations risk losing certifications, reimbursements, and legal credibility.

Furthermore, national quality assurance programs, like the UK Radiotherapy Board’s guidance on QA and the Radiation Oncology Safety Education and Information System (ROSEIS) in Australia, reinforce the importance of using phantoms for consistent dose verification and machine performance audits. Such regulatory frameworks ensure that radiation therapy is both safe and effective, fostering a continual rise in the demand for QA phantoms.

Download Free Sample Report

Key Market Challenges

High Cost and Limited Accessibility in Low-Resource Settings

Despite their clinical value, radiation therapy QA phantoms remain expensive, especially for advanced models designed for multi-modality systems. The high initial cost of QA phantoms, along with maintenance and calibration needs, acts as a barrier for widespread adoption in low- and middle-income countries (LMICs). According to the International Atomic Energy Agency (IAEA), more than 50% of cancer patients in LMICs lack access to radiotherapy, let alone comprehensive QA protocols. Budget constraints, inadequate infrastructure, and a shortage of trained personnel hinder the implementation of sophisticated QA systems, including phantoms.

Furthermore, even in developed regions, small clinics often struggle to justify investments in QA phantoms, particularly patient-specific or digital types, due to cost-benefit constraints. Many rely on outdated or shared phantoms, increasing the risk of machine errors and compromising treatment outcomes. Global health agencies are encouraging the deployment of low-cost, open-source QA phantom solutions, but scalability remains a major hurdle. Without financial incentives or subsidies, the market penetration of QA phantoms in underserved regions remains limited, affecting global standardization of radiation therapy.

Lack of Skilled Personnel and Training Programs

Effective use of QA phantoms requires specialized knowledge in radiation physics, dosimetry, and radiotherapy equipment. A significant challenge in the market is the shortage of trained radiation physicists and technologists capable of conducting and interpreting phantom-based QA assessments. The World Health Organization (WHO) estimates a global shortfall of over 18 million healthcare workers by 2030, including critical deficits in radiology and oncology expertise. In many developing countries, a single medical physicist may be responsible for multiple machines, compromising QA frequency and effectiveness.

Furthermore, existing training programs often do not provide adequate hands-on experience with advanced QA phantoms or automated systems. While initiatives like the IAEA’s Human Health Campus aim to bridge this gap through online education and workshops, the lack of localized training centers remains a bottleneck. Language barriers, lack of standardized curricula, and outdated teaching materials also contribute to inefficiencies. As radiation therapy becomes more technologically complex, the need for comprehensive and standardized QA training programs becomes more pressing to ensure consistent global practice.

Key Market Trends

Increasing Integration of 3D-Printed and Patient-Specific Phantoms

A growing trend in the radiation therapy QA market is the adoption of 3D-printed and patient-specific phantoms, driven by advancements in medical imaging and additive manufacturing. These phantoms are customized to replicate patient-specific anatomical structures, enabling more realistic simulation and enhanced precision in QA procedures. Unlike traditional homogeneous phantoms, 3D-printed versions can include varying densities and geometries, such as organs-at-risk (OARs) and tumors, which significantly improve the evaluation of treatment plans. Research institutions and hospitals globally are adopting open-source 3D printing technologies to fabricate QA phantoms using materials that closely mimic soft tissue, bone, and air cavities.

Publicly funded initiatives, such as the NIH’s 3D Print Exchange, provide templates and resources for developing anatomical models, including radiation phantoms. Moreover, academic institutions, like the University of Texas MD Anderson Cancer Center, have published studies highlighting the cost-efficiency and dosimetric accuracy of 3D-printed QA devices. This trend is further accelerated by the need for individualized treatment verification, especially in proton therapy and image-guided radiotherapy (IGRT), where precision is critical. As healthcare systems embrace personalized medicine, patient-specific QA phantoms are increasingly becoming a mainstay in radiotherapy quality assurance protocols.

Automation and AI Integration in QA Workflows

Another major trend shaping the market is the integration of artificial intelligence (AI) and automation in radiotherapy QA, which includes the use of smart phantoms capable of real-time data capture and feedback. These next-generation phantoms are embedded with sensors and connected to QA software systems, enabling automated measurement of parameters like beam alignment, dose distribution, and machine performance.

With rising patient volumes and complexity of treatments, manual QA processes are becoming inefficient and error prone. Automated QA systems using intelligent phantoms reduce human dependency, cut down testing time, and improve accuracy and reproducibility. Government-funded projects like the Radiotherapy AI Research from the U.S. National Institutes of Health (NIH) and UK’s NHS AI Lab are supporting the development of AI-enabled QA platforms to improve patient outcomes.

Furthermore, the American Association of Physicists in Medicine (AAPM) is actively promoting digital QA workflows, including automated phantom analysis, through updated guidelines and research publications. As hospitals adopt smart technologies to streamline operations and comply with value-based care models, the integration of AI into QA phantoms is expected to see strong growth.

Segmental Insights

Technology Insights

Based on Technology, the Linear Accelerators (LINACs) category holds the largest market share. This dominance is primarily attributed to the widespread adoption of linear accelerators in modern radiation oncology for delivering external beam radiation therapy with high precision and adaptability. Linear accelerators are the preferred technology in both developed and rapidly developing healthcare systems due to their ability to offer advanced treatment modalities such as Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiotherapy (SBRT), and Image-Guided Radiotherapy (IGRT). These treatment techniques demand rigorous and consistent quality assurance practices, including the use of specialized QA phantoms to verify dose delivery, image guidance, and patient positioning accuracy. As a result, QA phantoms tailored for LINAC-based systems are in higher demand compared to those used with other technologies. Moreover, governments and healthcare providers are increasingly replacing outdated technologies such as cobalt-60 machines with LINACs, especially in regions like North America, Europe, and parts of Asia. According to the International Atomic Energy Agency (IAEA), many cancer treatment centers are transitioning towards LINACs due to safety, flexibility, and effectiveness. This transition contributes to the sustained and growing use of QA phantoms designed for LINACs, further solidifying their lead in market share.

Download Free Sample Report

Regional Insights

Based on the region, North America holds the largest market share in the Global Radiation Therapy Quality Assurance (QA) Phantoms Market. This dominance is primarily driven by the region's highly advanced healthcare infrastructure, widespread adoption of radiation-based cancer treatments, and stringent regulatory frameworks. Countries like the United States and Canada have consistently invested in oncology care technologies, and the presence of globally recognized institutions such as the National Cancer Institute (NCI) and American Society for Radiation Oncology (ASTRO) further promotes the standardization of radiation therapy protocols, including mandatory quality assurance measures using phantoms. Moreover, North America leads in the implementation of cutting-edge radiotherapy techniques, including intensity-modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT), and proton therapy—all of which require high levels of precision and robust QA validation. As these techniques evolve, the demand for specialized phantoms to verify dosimetric accuracy, machine calibration, and treatment reproducibility grows correspondingly.

Key Market Players

• Computerized Imaging Reference Systems, Inc.
• Fluke Biomedical LLC.
• IBA Dosimetry Gmbh
• Modus Medical Devices Inc.
• PTW Freiburg GmbH
• Standard Imaging Inc.
• Sun Nuclear Corporation.
• The Phantom Laboratory Inc.
• Gammex Inc.
• Gold Standard Phantoms Limited

Report Scope:

In this report, the Global Radiation Therapy Quality Assurance Phantoms Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Radiation Therapy Quality Assurance Phantoms Market, By Technology:

o   Linear Accelerators

o   Cobalt-60

o   High-Dose Radiation

o   Low-Dose Radiation

• Radiation Therapy Quality Assurance Phantoms Market, By Therapy:

o   Photon Beam Radiation Therapy

o   Advanced 3-D Conformal Radiation Therapy

o   Image Guided Radiation Therapy

o   Intensity-modulated radiation therapy

o   Volumetric Modulated Arc Therapy

o   Intraoperative Radiotherapy

o   Neutron Beam Therapy

o   Brachytherapy

• Radiation Therapy Quality Assurance Phantoms Market, By Application:

o   Cancer

o   Breast Cancer

o   Lung Cancer

o   Colorectal Cancer

o   Head and Neck Cancers

o   Skin Cancer

o   Other

• Radiation Therapy Quality Assurance Phantoms Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Radiation Therapy Quality Assurance Phantoms Market.

Available Customizations:

Global Radiation Therapy Quality Assurance Phantoms Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Radiation Therapy Quality Assurance Phantoms Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]